KOACT 1000 FILM-COATED TABLETS 875MG/125MG [SIN16676P]

Product Info

KOACT 1000 FILM-COATED TABLETS 875MG/125MG

[SIN16676P]

Indication

Indications
Co-amoxiclav Tablets 875-125 mg is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics.
Co-amoxiclav Tablets 875-125 mg should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Co-amoxiclav Tablets 875-125 mg oral presentations for twice daily dosing, are indicated for short-term treatment of bacterial infections at the following sites:
Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis (AECB), lobar and bronchopneumonia.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. boils, abscesses, cellulitis, wound infections.
Bone and joint infections e.g. osteomyelitis.
Dental infections e.g. dentoalveolar abscess, pericoronitis, acute periodontitis.
Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
Susceptibility to Co-amoxiclav will vary with geography and time (see Pharmacological Properties, Pharmacodynamics for further information – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.

Dosing

Dosage and Administration
Pharmaceutical form: Film-coated tablets
Dosage depends on the age and renal function of the patient and the severity of the infection.
To minimise potential gastrointestinal intolerance, administer at the start of a meal. The absorption of Co-amoxiclav Tablets 875-125 mg is optimised when taken at the start of a meal.
Treatment should not be extended beyond 14 days without review.
Therapy can be started parenterally and continued with an oral preparation.
Tablets should be swallowed whole without chewing. If required, tablets may be broken in half and swallowed without chewing.
Co-amoxiclav Tablets 875-125 mg tablets are not recommended in children of 12 years and under.

Adults and Children over 12 years
The usual recommended daily dosage is:

Renal Impairment
No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 mL/min. The Co-amoxiclav Tablets 875-125 mg tablet should only be used in patients with a creatinine clearance (CrCl) rate of more than 30 mL/min.

Hepatic Impairment
Dose with caution; monitor hepatic function at regular intervals.

Contraindications

Contraindications
Co-amoxiclav Tablets 875-125 mg is contraindicated in patients with a history of hypersensitivity to betalactams, e.g. penicillins and cephalosporins.

Co-amoxiclav Tablets 875-125 mg is contraindicated in patients with a previous history of Co-amoxiclav Tablets 875-125 mg associated jaundice/hepatic dysfunction.